219 related articles for article (PubMed ID: 35205694)
21. CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses.
Yuan M; Webb E; Lemoine NR; Wang Y
Viruses; 2016 Mar; 8(3):72. PubMed ID: 26959050
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
23. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.
Wang L; Chen Y; Liu X; Li Z; Dai X
Front Oncol; 2021; 11():704999. PubMed ID: 35111663
[TBL] [Abstract][Full Text] [Related]
24. Advances in therapeutic application of CRISPR-Cas9.
Sun J; Wang J; Zheng D; Hu X
Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
[TBL] [Abstract][Full Text] [Related]
25. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses.
Gilani U; Shaukat M; Rasheed A; Shahid M; Tasneem F; Arshad M; Rashid N; Shahzad N
J Med Virol; 2019 Jan; 91(1):1-13. PubMed ID: 30133783
[TBL] [Abstract][Full Text] [Related]
26. CRISPR-Cas9 for medical genetic screens: applications and future perspectives.
Xue HY; Ji LJ; Gao AM; Liu P; He JD; Lu XJ
J Med Genet; 2016 Feb; 53(2):91-7. PubMed ID: 26673779
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.
Hazafa A; Mumtaz M; Farooq MF; Bilal S; Chaudhry SN; Firdous M; Naeem H; Ullah MO; Yameen M; Mukhtiar MS; Zafar F
Life Sci; 2020 Dec; 263():118525. PubMed ID: 33031826
[TBL] [Abstract][Full Text] [Related]
28. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
29. Gene Editing in Clinical Practice: Where are We?
Mittal RD
Indian J Clin Biochem; 2019 Jan; 34(1):19-25. PubMed ID: 30728669
[TBL] [Abstract][Full Text] [Related]
30. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.
Liu T; Shen JK; Li Z; Choy E; Hornicek FJ; Duan Z
Cancer Lett; 2016 Apr; 373(1):109-118. PubMed ID: 26806808
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
33. The Potential Therapeutic Applications of CRISPR/Cas9 in the Treatment of Gastrointestinal Cancers.
Mehrabadi S; Salmani Izadi F; Pasha S; Pourali R; Khazaei M; Hassanian SM; Ferns GA; Avan A
Curr Mol Med; 2024 Jan; ():. PubMed ID: 38243923
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma.
Hong L; Zhang C; Jiang Y; Liu H; Huang H; Guo D
Future Oncol; 2020 Jun; 16(16):1125-1136. PubMed ID: 32338048
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/Cas9 for cancer research and therapy.
Zhan T; Rindtorff N; Betge J; Ebert MP; Boutros M
Semin Cancer Biol; 2019 Apr; 55():106-119. PubMed ID: 29673923
[TBL] [Abstract][Full Text] [Related]
36. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
37. Immune responses to CRISPR-Cas protein.
Roy S
Prog Mol Biol Transl Sci; 2021; 178():213-229. PubMed ID: 33685598
[TBL] [Abstract][Full Text] [Related]
38. A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing.
Chen XZ; Guo R; Zhao C; Xu J; Song H; Yu H; Pilarsky C; Nainu F; Li JQ; Zhou XK; Zhang JY
Front Pharmacol; 2022; 13():939090. PubMed ID: 35935840
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications.
Assis AJB; Santana BLO; Gualberto ACM; Pittella-Silva F
Front Pharmacol; 2023; 14():1322937. PubMed ID: 38130408
[TBL] [Abstract][Full Text] [Related]
40. Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.
Mehravar M; Roshandel E; Salimi M; Chegeni R; Gholizadeh M; Mohammadi MH; Hajifathali A
Immunol Lett; 2020 Oct; 226():71-82. PubMed ID: 32687855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
